| Online-Ressource |
Verfasst von: | Puris, Elena [VerfasserIn]  |
| Petralla, Sabrina [VerfasserIn]  |
| Auriola, Seppo [VerfasserIn]  |
| Kidron, Heidi [VerfasserIn]  |
| Fricker, Gert [VerfasserIn]  |
| Gynther, Mikko [VerfasserIn]  |
Titel: | Monoacylglycerol lipase inhibitor JJKK048 ameliorates ABCG2 transporter-mediated regorafenib resistance induced by hypoxia in triple negative breast cancer cells |
Verf.angabe: | Elena Puris, Sabrina Petralla, Seppo Auriola, Heidi Kidron, Gert Fricker, Mikko Gynther |
E-Jahr: | 2023 |
Jahr: | 15 August 2023 |
Umfang: | 10 S. |
Fussnoten: | Online verfügbar 21 May 2023, Version des Artikels 15 August 2023 ; Gesehen am 16.10.2023 |
Titel Quelle: | Enthalten in: Journal of pharmaceutical sciences |
Ort Quelle: | Amsterdam : Elsevier, 1911 |
Jahr Quelle: | 2023 |
Band/Heft Quelle: | 112(2023), 9 vom: Sept., Seite 2581-2590 |
ISSN Quelle: | 1520-6017 |
Abstract: | Triple negative breast cancer (TNBC) is among the most aggressive and deadly cancer subtypes. Intra-tumoral hypoxia is associated with aggressiveness and drug resistance in TNBC. One of the underlying mechanisms of hypoxia-induced drug resistance is the elevated expression of efflux transporters such as breast cancer resistant protein (ABCG2). In the present study, we investigated the possibility of ameliorating ABCG2-mediated drug resistance in hypoxic TNBC cells by monoacylglycerol lipase (MAGL) inhibition and the consequent downregulation of ABCG2 expression. The effect of MAGL inhibition on ABCG2 expression, function, and efficacy of regorafenib, an ABCG2 substrate was investigated in cobalt dichloride (CoCl2) induced pseudohypoxic TNBC (MDA-MB-231) cells, using quantitative targeted absolute proteomics, qRT-PCR, anti-cancer drug accumulation in the cells, cell invasiveness and resazurin-based cell viability assays. Our results showed that hypoxia-induced ABCG2 expression led to low regorafenib intracellular concentrations, reduced the anti-invasiveness efficacy, and elevated half maximal inhibitory concentration (IC50) of regorafenib in vitro MDA-MB-231 cells. MAGL inhibitor, JJKK048, reduced ABCG2 expression, increased regorafenib cell accumulation, which led to higher regorafenib efficacy. In conclusion, hypoxia-induced regorafenib resistance due to ABCG2 over-expression in TNBC cells can be ameliorated by MAGL inhibition. |
DOI: | doi:10.1016/j.xphs.2023.05.012 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.xphs.2023.05.012 |
| Volltext: https://www.sciencedirect.com/science/article/pii/S0022354923001983 |
| DOI: https://doi.org/10.1016/j.xphs.2023.05.012 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Anti-cancer drug resistance |
| Breast cancer resistance protein |
| Hypoxia |
| Monoacylglycerol lipase |
| Triple negative breast cancer |
K10plus-PPN: | 1865711438 |
Verknüpfungen: | → Zeitschrift |
Monoacylglycerol lipase inhibitor JJKK048 ameliorates ABCG2 transporter-mediated regorafenib resistance induced by hypoxia in triple negative breast cancer cells / Puris, Elena [VerfasserIn]; 15 August 2023 (Online-Ressource)